Dionysios Chartoumpekis

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


56 publications

In press | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2006 |
In press
 
Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice.
Yagishita Y., Uruno A., Chartoumpekis D.V., Kensler T.W., Yamamoto M. The Journal of endocrinology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_06EF9288E390]
2024
kmerDB: A database encompassing the set of genomic and proteomic sequence information for each species.
Mouratidis I., Baltoumas F.A., Chantzi N., Patsakis M., Chan CSY, Montgomery A., Konnaris M.A., Aplakidou E., Georgakopoulos G.C., Das A. et al., 2024/12. Computational and structural biotechnology journal, 23 pp. 1919-1928. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_00E21235BAF6]
Predictors and weight impact of postbariatric hypoglycemia after Roux-en-Y gastric bypass surgery: a prospective observational cohort study.
Lüscher A., Vionnet N., Pasquier J., Chartoumpekis D., Mantziari S., Wojtsusizyn A., Favre L., 2024/12. Surgery for obesity and related diseases, 20 (12) pp. 1187-1195. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6263CAFF4705]
 
A review on cell-free RNA profiling: Insights into metabolic diseases and predictive value for bariatric surgery outcomes.
Mareboina M., Deng E., Mouratidis I., Yee N.S., Pitteloud N., Georgakopoulos-Soares I., Chartoumpekis D.V., 2024/09. Molecular metabolism, 87 p. 101987. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BD997FF1E914]
Adipocyte-specific Nrf2 deletion negates nitro-oleic acid benefits on glucose tolerance in diet-induced obesity.
Chartoumpekis D.V., Chen I., Salvatore S.R., Schopfer F.J., Freeman B.A., Khoo NKH, 2024/08/01. Nitric oxide, 149 pp. 75-84. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_23D373CD67DD]
Traditional Chinese Medicine for Hashimoto's Thyroiditis: Focus on Selenium and Antioxidant Phytochemicals.
Huang S., Ziros P.G., Chartoumpekis D.V., Psarias G., Duntas L., Zuo X., Li X., Ding Z., Sykiotis G.P., 2024/07/19. Antioxidants, 13 (7). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_233E52AB6144]
Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative review.
Chartoumpekis D.V., Habeos E.E., Psilopanagioti A., 2024/06. Obesity pillars, 10 p. 100104. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_AC09ECDD5B62]
Transcriptomic profiling of the response to excess iodide in Keap1 hypomorphic mice reveals new gene-environment interactions in thyroid homeostasis.
Ziros P.G., Chartoumpekis D.V., Georgakopoulos-Soares I., Psarias G., Sykiotis G.P., 2024/02. Redox biology, 69 p. 102978. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC6F475A89B3]
2023
Impact of Preoperative Psychiatric Profile in Bariatric Surgery on Long-term Weight Outcome.
Lüscher A., Vionnet N., Amiguet M., Chartoumpekis D., Mantziari S., Frantz J., Favre L., 2023/07. Obesity surgery, 33 (7) pp. 2072-2082. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_921A9655D607]
 
Screening of natural compounds for antioxidant transcriptional activity and effects on the thyroid
Ziros Panos, Psarias Georgios, Chartoumpekis Dionysios, Sykiotis Gerasimos P., 2023/05. Free Radical Biology and Medicine, 201 pp. 35-36.
[DOI][WoS][serval:BIB_0715079035F4]
Agonistes des récepteurs du GLP-1 et du GIP : des thérapies émergentes de l’obésité [GLP-1 and GIP receptor agonists: emerging therapies for obesity]
Chartoumpekis D., Favre L., 2023/03/22. Revue medicale suisse, 19 (819) pp. 555-561. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_2F22CFFBB46E]
NRF2 and the Moirai: Life and Death Decisions on Cell Fates.
Yagishita Y., Chartoumpekis D.V., Kensler T.W., Wakabayashi N., 2023/03. Antioxidants & redox signaling, 38 (7-9) pp. 684-708. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_61FB61237DF3]
2022
Glucagon-like Peptide-1 Receptor in the Human Hypothalamus Is Associated with Body Mass Index and Colocalizes with the Anorexigenic Neuropeptide Nucleobindin-2/Nesfatin-1.
Psilopanagioti A., Nikou S., Logotheti S., Arbi M., Chartoumpekis D.V., Papadaki H., 2022/11/28. International journal of molecular sciences, 23 (23) p. 14899. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2F421634155D]
 
Maternal Calorie Restriction Induces a Transcriptional Cytoprotective Response in Embryonic Liver Partially Dependent on Nrf2.
Habeos G.I., Filippopoulou F., Habeos E.E., Kalaitzopoulou E., Skipitari M., Papadea P., Lagoumintzis G., Niarchos A., Georgiou C.D., Chartoumpekis D.V., 2022/11/17. Antioxidants, 11 (11). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EEC1C794C6E8]
Emerging roles of Keap1/Nrf2 signaling in the thyroid gland and perspectives for bench-to-bedside translation.
Chartoumpekis D.V., Ziros P.G., Habeos I.G., Sykiotis G.P., 2022/09. Free radical biology & medicine, 190 pp. 276-283. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_415D504588B6]
 
Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece.
Parthymou A., Habeos E.E., Habeos G.I., Deligakis A., Livieratos E., Marangos M., Chartoumpekis D.V., 2022/05/19. BMJ open, 12 (5) pp. e057084. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_188625FDC876]
Editorial: Microbiota and mitochondria: Impact on cell signaling, physiology, and disease.
Chartoumpekis D.V., Zaravinos A., Apidianakis Y., Lagoumintzis G., 2022. Frontiers in microbiology, 13 p. 1056499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_48F88A71E088]
2021
Dexamethasone Administration in Mice Leads to Less Body Weight Gain over Time, Lower Serum Glucose, and Higher Insulin Levels Independently of NRF2.
Filippopoulou F., Habeos G.I., Rinotas V., Sophocleous A., Sykiotis G.P., Douni E., Chartoumpekis D.V., 2021/12/21. Antioxidants, 11 (1) p. 4. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2BFF57D4A6C3]
 
Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice.
Rush B.M., Bondi C.D., Stocker S.D., Barry K.M., Small S.A., Ong J., Jobbagy S., Stolz D.B., Bastacky S.I., Chartoumpekis D.V. et al., 2021/01. Kidney international, 99 (1) pp. 102-116. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EE6812558D88]
Mice Hypomorphic for Keap1, a Negative Regulator of the Nrf2 Antioxidant Response, Show Age-Dependent Diffuse Goiter with Elevated Thyrotropin Levels.
Ziros P.G., Renaud C.O., Chartoumpekis D.V., Bongiovanni M., Habeos I.G., Liao X.H., Refetoff S., Kopp P.A., Brix K., Sykiotis G.P., 2021/01. Thyroid, 31 (1) pp. 23-35. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62561B304595]
2020
Patent Review (2017-2020) of the Keap1/Nrf2 Pathway Using PatSeer Pro: Focus on Autoimmune Diseases.
Chartoumpekis D.V., Fu C.Y., Ziros P.G., Sykiotis G.P., 2020/11/17. Antioxidants, 9 (11) pp. E1138. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E93BD1550E44]
The Keap1/Nrf2 Signaling Pathway in the Thyroid-2020 Update.
Thanas C., Ziros P.G., Chartoumpekis D.V., Renaud C.O., Sykiotis G.P., 2020/11/04. Antioxidants, 9 (11) pp. E1082. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F5831CDC48DF]
The Transcriptomic Response of the Murine Thyroid Gland to Iodide Overload and the Role of the Nrf2 Antioxidant System.
Chartoumpekis D.V., Ziros P.G., Georgakopoulos-Soares I., Smith AAT, Marques A.C., Ibberson M., A Kopp P., Habeos I., Trougakos I.P., Khoo NKH et al., 2020/09/18. Antioxidants, 9 (9) pp. E884. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F9FB94E92E22]
 
Sulforaphane Diminishes the Formation of Mammary Tumors in Rats Exposed to 17β-Estradiol.
Palliyaguru D.L., Yang L., Chartoumpekis D.V., Wendell S.G., Fazzari M., Skoko J.J., Liao Y., Oesterreich S., Michalopoulos G.K., Kensler T.W., 2020/07/30. Nutrients, 12 (8). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AFF6BBE45853]
Rare and common genetic variations in the Keap1/Nrf2 antioxidant response pathway impact thyroglobulin gene expression and circulating levels, respectively.
Matana A., Ziros P.G., Chartoumpekis D.V., Renaud C.O., Polašek O., Hayward C., Zemunik T., Sykiotis G.P., 2020/03. Biochemical pharmacology, 173 p. 113605. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E02568FE6AA]
EMT Factors and Metabolic Pathways in Cancer.
Georgakopoulos-Soares I., Chartoumpekis D.V., Kyriazopoulou V., Zaravinos A., 2020. Frontiers in oncology, 10 p. 499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_288EE66373A2]
2019
A Bibliometric Review of the Keap1/Nrf2 Pathway and its Related Antioxidant Compounds.
Paunkov A., Chartoumpekis D.V., Ziros P.G., Sykiotis G.P., 2019/09/01. Antioxidants, 8 (9). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_11053F010468]
Interaction of Genetic Variations in NFE2L2 and SELENOS Modulates the Risk of Hashimoto's Thyroiditis.
Santos L.R., Durães C., Ziros P.G., Pestana A., Esteves C., Neves C., Carvalho D., Bongiovanni M., Renaud C.O., Chartoumpekis D.V. et al., 2019/09. Thyroid, 29 (9) pp. 1302-1315. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D7B155BB39D0]
Broccoli sprout beverage is safe for thyroid hormonal and autoimmune status: Results of a 12-week randomized trial.
Chartoumpekis D.V., Ziros P.G., Chen J.G., Groopman J.D., Kensler T.W., Sykiotis G.P., 2019/04. Food and chemical toxicology, 126 pp. 1-6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A1B894228A4D]
 
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.
Khoo NKH, Fazzari M., Chartoumpekis D.V., Li L., Guimaraes D.A., Arteel G.E., Shiva S., Freeman B.A., 2019/04. Redox biology, 22 p. 101132. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7118C0B5642F]
Impact of Antioxidant Natural Compounds on the Thyroid Gland and Implication of the Keap1/Nrf2 Signaling Pathway.
Paunkov A., Chartoumpekis D.V., Ziros P.G., Chondrogianni N., Kensler T.W., Sykiotis G.P., 2019. Current pharmaceutical design, 25 (16) pp. 1828-1846. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E14A050AB1CD]
2018
 
Nrf2 deletion from adipocytes, but not hepatocytes, potentiates systemic metabolic dysfunction after long-term high-fat diet-induced obesity in mice.
Chartoumpekis D.V., Palliyaguru D.L., Wakabayashi N., Fazzari M., Khoo NKH, Schopfer F.J., Sipula I., Yagishita Y., Michalopoulos G.K., O'Doherty R.M. et al., 2018/08/01. American journal of physiology. Endocrinology and metabolism, 315 (2) pp. E180-E195. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_86516E1F83C3]
 
NFE2-Related Transcription Factor 2 Coordinates Antioxidant Defense with Thyroglobulin Production and Iodination in the Thyroid Gland.
Ziros P.G., Habeos I.G., Chartoumpekis D.V., Ntalampyra E., Somm E., Renaud C.O., Bongiovanni M., Trougakos I.P., Yamamoto M., Kensler T.W. et al., 2018/06. Thyroid, 28 (6) pp. 780-798. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3646DC129157]
 
Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice.
Chartoumpekis D.V., Yagishita Y., Fazzari M., Palliyaguru D.L., Rao U.N., Zaravinos A., Khoo N.K., Schopfer F.J., Weiss K.R., Michalopoulos G.K. et al., 2018/03/08. JCI insight, 3 (5). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4D3614D995B8]
2016
 
Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms.
Palliyaguru D.L., Chartoumpekis D.V., Wakabayashi N., Skoko J.J., Yagishita Y., Singh S.V., Kensler T.W., 2016/12. Free radical biology & medicine, 101 pp. 116-128. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_746390FB4DC0]
 
Keap1 hypomorphism protects against ischemic and obstructive kidney disease.
Tan R.J., Chartoumpekis D.V., Rush B.M., Zhou D., Fu H., Kensler T.W., Liu Y., 2016/11/02. Scientific reports, 6 p. 36185. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_85C46D57D0F8]
 
Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet.
Slocum S.L., Skoko J.J., Wakabayashi N., Aja S., Yamamoto M., Kensler T.W., Chartoumpekis D.V., 2016/02/01. Archives of biochemistry and biophysics, 591 pp. 57-65. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5E450088756E]
A Simple Protocol for High Efficiency Protein Isolation After RNA Isolation from Mouse Thyroid and Other Very Small Tissue Samples.
Ziros P.G., Chartoumpekis D.V., Sykiotis G.P., 2016. Methods in molecular biology, 1449 pp. 383-393. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F6CEDB51975B]
Hepatic Fgf21 Expression Is Repressed after Simvastatin Treatment in Mice.
Ziros P., Zagoriti Z., Lagoumintzis G., Kyriazopoulou V., Iskrenova R.P., Habeos E.I., Sykiotis G.P., Chartoumpekis D.V., Habeos I.G., 2016. Plos One, 11 (9) pp. e0162024. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_940B3CBCD2E3]
2015
 
Crosstalk between Nrf2 and Notch signaling.
Wakabayashi N., Chartoumpekis D.V., Kensler T.W., 2015/11. Free radical biology & medicine, 88 (Pt B) pp. 158-167. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_22A0F91E49DE]
 
Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism.
Chartoumpekis D.V., Wakabayashi N., Kensler T.W., 2015/08. Biochemical Society transactions, 43 (4) pp. 639-644. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1EA517DBB84B]
 
Notch intracellular domain overexpression in adipocytes confers lipodystrophy in mice.
Chartoumpekis D.V., Palliyaguru D.L., Wakabayashi N., Khoo N.K., Schoiswohl G., O'Doherty R.M., Kensler T.W., 2015/07. Molecular metabolism, 4 (7) pp. 543-550. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AE797B6F9053]
2014
 
Genetic or pharmacologic activation of Nrf2 signaling fails to protect against aflatoxin genotoxicity in hypersensitive GSTA3 knockout mice.
Kensler K.H., Slocum S.L., Chartoumpekis D.V., Dolan P.M., Johnson N.M., Ilic Z., Crawford D.R., Sell S., Groopman J.D., Kensler T.W. et al., 2014/06. Toxicological sciences, 139 (2) pp. 293-300. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9699494A7295]
 
Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by notch signaling.
Wakabayashi N., Skoko J.J., Chartoumpekis D.V., Kimura S., Slocum S.L., Noda K., Palliyaguru D.L., Fujimuro M., Boley P.A., Tanaka Y. et al., 2014/02. Molecular and cellular biology, 34 (4) pp. 653-663. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3018EF22B4D3]
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Chartoumpekis D.V., Sykiotis G.P., 2014. New England Journal of Medicine, 370 (18) p. 1767.
[URN][WoS][Pmid][serval:BIB_3EE4B1733A5A]
2013
 
New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome.
Chartoumpekis D.V., Kensler T.W., 2013/03/01. Current diabetes reviews, 9 (2) pp. 137-145. Peer-reviewed.
[DOI][Pmid][serval:BIB_44782D2AF61A]
 
Hepatic gene expression profiling in Nrf2 knockout mice after long-term high-fat diet-induced obesity.
Chartoumpekis D.V., Ziros P.G., Zaravinos A., Iskrenova R.P., Psyrogiannis A.I., Kyriazopoulou V.E., Sykiotis G.P., Habeos I.G., 2013. Oxidative Medicine and Cellular Longevity, 2013 p. 340731. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C12D65A41242]
 
Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros P.G., Manolakou S.D., Habeos I.G., Lilis I., Chartoumpekis D.V., Koika V., Soares P., Kyriazopoulou V.E., Scopa C.D., Papachristou D.J. et al., 2013. Journal of Clinical Endocrinology and Metabolism, 98 (8) pp. E1422-E1427. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_93C277B91627]
2012
 
Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice.
Chartoumpekis D.V., Zaravinos A., Ziros P.G., Iskrenova R.P., Psyrogiannis A.I., Kyriazopoulou V.E., Habeos I.G., 2012. PloS one, 7 (4) pp. e34872. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_23A9B9F7CA37]
2011
 
Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21.
Chartoumpekis D.V., Habeos I.G., Ziros P.G., Psyrogiannis A.I., Kyriazopoulou V.E., Papavassiliou A.G., 2011. Molecular medicine, 17 (7-8) pp. 736-740. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_832AD6DB73D7]
 
Nrf2 activation diminishes during adipocyte differentiation of ST2 cells.
Chartoumpekis D.V., Ziros P.G., Sykiotis G.P., Zaravinos A., Psyrogiannis A.I., Kyriazopoulou V.E., Spandidos D.A., Habeos I.G., 2011. International Journal of Molecular Medicine, 28 (5) pp. 823-828.
[DOI][WoS][Pmid][serval:BIB_968ED398C455]
 
Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice.
Chartoumpekis D.V., Ziros P.G., Psyrogiannis A.I., Papavassiliou A.G., Kyriazopoulou V.E., Sykiotis G.P., Habeos I.G., 2011. Diabetes, 60 (10) pp. 2465-2473. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BCF8EA8299B9]
2010
 
Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway.
Chartoumpekis D., Ziros P.G., Psyrogiannis A., Kyriazopoulou V., Papavassiliou A.G., Habeos I.G., 2010/05/28. Biochemical and biophysical research communications, 396 (2) pp. 463-466. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AB1C99FFA90F]
2008
 
Simvastatin activates Keap1/Nrf2 signaling in rat liver.
Habeos I.G., Ziros P.G., Chartoumpekis D., Psyrogiannis A., Kyriazopoulou V., Papavassiliou A.G., 2008/11. Journal of molecular medicine, 86 (11) pp. 1279-1285. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BD3A484B29F0]
2006
 
Calciphylaxis: a complication of end-stage renal disease improved by parathyroidectomy.
Maroulis J.C., Fourtounas C., Vlachojannis J.G., Siasos N., Karavias D., Chartoumpekis D., Habeos I., 2006. Hormones, 5 (3) pp. 210-213. Peer-reviewed.
[DOI][Pmid][serval:BIB_05DA97E5B9E2]
 
Fibrocalculous pancreatic diabetes in patient residing in the Mediterranean region.
Habeos I., Kyriazopoulou V., Chartoumpekis D., Psyrogiannis A., 2006. Hormones, 5 (1) pp. 64-66. Peer-reviewed.
[DOI][Pmid][serval:BIB_A40CD24AE059]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University